menu
    • menu
    [{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Not Applicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Not Applicable"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Not Applicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ PharmaEssentia"},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"12","companyTruncated":"Athenex \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"Microtubule","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Not Applicable"},{"orgOrder":0,"company":"Almirall","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Tirbanibulin","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Almirall \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Almirall \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tirbanibulin

    Menu

    Tirbanibulin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            FDA Approves Almirall’s Klisyri® for Actinic Keratosis on Expanded Facial Areas

                            Details : KLISYRI (tirbanibulin) is an approved microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2024

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Almirall's Klisyri® (tirbanibulin) Receives Strong Recommendation in American Academy of Dermatology AK Guide...

                            Details : KLISYRI (tirbanibulin) met key clinical criteria required for its inclusion with 49% of KLISYRI patients achieving complete clearance (100%) of lesions (9% for vehicle) and no patients withdrew from clinical trials due to adverse events.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 18, 2022

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Athenex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Athenex Announces Phased European Launch of Klisyri® (tirbanibulin) for the Treatment of Actinic Keratosis

                            Details : Klisyri® (tirbanibulin) is a novel, topical first-in-class microtubule inhibitor with a selective antiproliferative mechanism of action that we believe represents a significant step forward in the treatment of actinic keratosis (AK) of the face and scal...

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 27, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Athenex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Seqirus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Athenex Announces Additional License Agreement for Tirbanibulin

                            Details : Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand, and AVIR will have an exclusive license to commercialize tirbanibulin in Canada.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 26, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Seqirus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Seqirus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Athenex Announces Additional Licensing Agreements for Tirbanibulin

                            Details : Under the terms of the agreements, Seqirus will have an exclusive license to commercialize tirbanibulin in Australia and New Zealand, and AVIR will have an exclusive license to commercialize tirbanibulin in Canada.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            July 26, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Seqirus

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Almirall Receives European Commission approval of Klisyri®▼ (tirbanibulin) for Actinic Keratosis

                            Details : Klisyri® (tirbanibulin) is a topical microtubule inhibitor indicated for the treatment of actinic keratosis (AK) of the face or scalp in adults and it acts through a selective antiproliferative mechanism of action.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 19, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Almirall Receives Positive CHMP Opinion for Klisyri®▼ (Tirbanibulin), An Innovative Topical Treatment for A...

                            Details : In the KX01-AK-004 study, complete clearance was observed in 54% of the patients treated with tirbanibulin versus 13% for vehicle-treated groups.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 21, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Almirall

                            Spain arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Almirall U.S. Launches Klisyri® (tirbanibulin), a New, Innovative Topical Treatment for Actinic Keratosis

                            Details : Klisyri® is a novel, topical, first-in-class microtubule inhibitor that represents a significant step forward in the treatment of AK due to its short treatment protocol (once daily application for 5 days), and proven efficacy and safety profile.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 18, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

                            Details : PharmaEssentia (PEC) adds licensing rights to tirbanibulin for Japan and South Korea to already licensed territories, which include Taiwan, Singapore, and Malaysia.

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 18, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : PharmaEssentia

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Athenex

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Almirall

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Athenex Announces U.S. Launch of Klisyri® and Licensing of Additional Territories for Tirbanibulin

                            Details : Klisyri (tirbanibulin) is a microtubule inhibitor indicated for the topical treatment of actinic keratosis of the face or scalp. Tirbanibulin ointment 1% (10 mg/g) or vehicle, was self-administered to 25 cm2 of the face or scalp encompassing 4-8 typical ...

                            Brand Name : Klisyri

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 18, 2021

                            Lead Product(s) : Tirbanibulin

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Almirall

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth